Introduction: NSCLC is the leading cause of cancer mortality. Recent retrospective clinical analyses suggest that blocking the receptor activator of NF-kB (RANK) signaling pathway inhibits the growth of NSCLC and might represent a new treatment strategy.
Introduction
With more than 1.5 million deaths yearly, lung cancer has become the leading cause of cancer-related mortality worldwide, with NSCLC representing 80% to 85% of cases. 1 Although new therapies are emerging to combat lung adenocarcinoma, which is the main histological subtype of NSCLC, their use is currently limited to a subset of molecularly selected patients, and no specific targeted therapy has demonstrated activity against tumors carrying the most frequently mutated proto-oncogene, KRAS.
2 One interesting approach for cancer treatment is to identify actionable membrane-bound or secreted ligandreceptor systems that act in the tumor environment to promote disease progression, which can be very selectively blocked through the use of small compounds or antibodies. One such example is the tumor necrosis factor (TNF) family member, receptor activator of NF-kB (RANK) ligand (RANKL) that signals through its receptor RANK, which was first discovered for communication between T cells and dendritic cells. 3 Through its receptor RANK, RANKL activates osteoclasts for bone resorption, promotes lymphocyte maturation and function, and enables mammary gland and secondary lymph node organogenesis. [4] [5] [6] A link between RANKL signaling and cancer has been established in recent years: first, and perhaps owing to its bone remodeling capabilities, the RANKL-RANK pathway facilitates bone metastasis formation 7, 8 ; second, it promotes seeding of breast tumor cells into the lungs in a T-regulatory-cell-dependent manner 9 ; third, it participates in development of progestin-dependent mammary tumors. 10, 11 The importance of this signaling pathway in primary breast cancer is well documented, with RANKL mRNA being stabilized in response to progesterone, leading to increased RANKL protein expression that promotes tumor cell proliferation 12 and epithelialmesenchymal transition to foster tumor cell migration. 13 In contrast, much less is known about its contribution in primary tumors from other carcinomas such as lung cancer. Recently, in a large international clinical trial of patients with advanced solid tumors (excluding breast and prostate cancer) or multiple myeloma, denosumab, a fully human monoclonal antibody that binds RANKL and blocks RANKL-RANK interaction, demonstrated activity in preventing bone metastasis-related adverse events, such as fracture or the need for radiotherapy. Although this trial failed to reveal any difference in overall survival (OS), 14 a retrospective subgroup analysis from this trial reported increased OS specifically in patients with NSCLC. 15, 16 In our study, we sought to investigate the involvement of RANKL in primary tumors from NSCLC by using genetically engineered mouse models.
Material and Methods

Animal Models
K-ras LSL-G12D/WT (K) and p53 FL/FL mice in a C57BL6/J background were purchased from The Jackson Laboratory (Bar Harbor, ME) and bred together to obtain K-ras LSL-G12D/WT ; p53 FL/FL (KP) mice. Lkb1 FL/FL mice in a mixed background (FVB; 129S6) were obtained from R. Receptor activator of NF-kB ligand gene (RANKL) expression correlates with poor overall survival and KRAS mutation in human lung adenocarcinoma. (A) Kaplan-Meier curves for overall survival, hazard ratios (HRs), confidence intervals, and p values of pairwise differences between groups with high or low RANKL expression in the Lung-1 (left) and The Cancer Genome Atlas (TCGA) lung adenocarcinoma (right) data sets. Differences between curves were assessed by using the log rank test (Mantel-Cox 
Mouse Treatment Modalities
Recombinant RANK (mouse):Fc (human) fusion and human Fc immunoglobulin G1 control proteins were purchased from AdipoGen Life Sciences (Liestal, Switzerland). Mice were treated with 10 mg/kg of RANK-Fc or Fc control by subcutaneous injection twice weekly. Cisplatin was used at 3.5 mg/kg in sterile phosphate-buffered saline by intraperitoneal injection.
Study Approval
All mouse experiments were performed with permission of the Veterinary Authority of the Canton de Vaud, Switzerland (license number VD2391).
Results and Discussion
RANKL Expression Correlates with Poor OS and KRAS Mutation in Lung Adenocarcinoma
To test the hypothesis that RANKL signaling regulates the development of primary lung tumors, we interrogated two independent publicly available gene expression data sets of human lung adenocarcinoma, and one of colorectal cancer (CRC). It revealed that high expression of RANKL (also known as TNF superfamily member 11 gene [TNFSF11]) was associated with a reduced OS compared with that of tumor samples with low expression in lung adenocarcinoma but not in CRC. RANK (also known as TNF receptor superfamily member 11A [TNFRSF11A]) expression was also associated with reduced OS, but only in one of the two lung data sets, whereas it was linked with better OS for patients with CRC ( Fig. 1A and Supplementary Fig. 1A-D) , suggesting a peculiar relationship between RANK/RANKL signaling and lung cancer progression that is not shared by CRC. Specific data analysis from The Cancer Genome Atlas (TCGA [https:// tcga-data.nci.nih.gov/tcga/]) also showed that RANKL expression was significantly stronger in KRAS-mutant than in KRAS wild-type (WT) tumors in lung adenocarcinoma but not in CRC (Fig. 1B) . KRAS mutation itself in lung adenocarcinoma is not prognostic of poor OS as reported earlier 17 ( Supplementary Fig. 1E ). Recently, gene expression analysis from TCGA enabled to define biologically distinct KRAS-mutant lung tumors in function of cooccurring mutations in tumor suppressors. 18 Specifically, this analysis highlighted three different subgroups, called KC (mutant for KRAS and enriched for CDKN2A mutations), KP (mutant for KRAS and enriched for TP53 mutations), and KL (mutant for KRAS and enriched for liver kinase B1 gene [LKB1] mutations). Analogies were drawn between cluster-specific biological signatures and tumors from different mouse models of oncogenic Kras-dependent lung tumorigenesis. For example, gene set enrichment analysis of the KL cluster retrieved gene signatures obtained from murine lung tumors expressing mutant Kras(G12D) and deficient for Lkb1. 18 Intrigued by these analogies, we decided to compare RANKL expression between each cluster. This analysis showed that RANKL levels are significantly higher in the KL cluster than in the KP cluster (p ¼ 9.6e-07 [ Fig. 1C] ). From each of the KRAS-mutant and KRAS WT group, as well as from the KC, KL, and KP clusters from KRAS-mutant tumors, we interrogated the genes most positively correlated with RANKL (Supplementary  Table 1 ). This analysis revealed hallmark pathways of cell cycle, mammalian target of rapamycin signaling, epithelial-mesenchymal transition (EMT), hypoxia, and glycolysis in the KRAS-mutant samples. In contrast, RANKLcorrelated genes in KRAS WT tumor samples revealed pathways representing EMT, inflammatory and angiogenic responses, and interestingly, KRAS signaling. KRAS-mutant subgroup analysis highlighted further differences between the clusters, with enrichments for pathways of cell cycle and EMT in KC; cell cycle and mammalian target of rapamycin signaling in KL; and inflammatory and immune responses, KRAS signaling, and EMT in KP (see Supplementary Table 1) . Thus, RANKL expression, which is stronger in KRAS-mutant samples than in KRAS WT samples, is associated with poor OS in human lung adenocarcinoma. Within KRAS-mutant tumors, expression of RANKL is the strongest in a subgroup of tumors harboring LKB1 mutations.
Pharmacological Blockade of Rankl Inhibits Tumor Growth in Mouse Models of Lung Adenocarcinoma
The human data prompted us to investigate the possibility that RANKL signaling contributes to primary (designated as K hereafter) and K-ras LSL-G12D/WT ; Lkb1 FL/FL (KL). In these models, tumor initiation is triggered in adult mice upon intratracheal delivery of viruses carrying the Cre recombinase, resulting in oncogenic Kras(G12D) activation (K), or Kras(G12D) activation concomitantly with deletion of tumor suppressor Lkb1 (KL). Loss of Lkb1 enables tumor progression toward aggressive adenocarcinoma, with transdifferentiation to squamous cell carcinoma in some cases. [19] [20] [21] For preclinical relevance, mice were treated with RANK-Fc or control Fc only when tumors were well established and visible by microcomputed tomography (mCT). Short-term (2 weeks for K and 1 week for KL mice) RANK-Fc treatment led to a significantly diminished tumor growth rate, with tumor shrinkage (i.e., relative growth <1) detected in multiple tumors, as monitored by mCT ( Fig. 2A) . This response was accompanied by a reduced proliferation of tumor cells (Ki67 staining) and reduced phospho-Erk, a marker of advanced grade in Kras-mutant lung tumors, 22, 23 specifically in KL tumors. No change in apoptosis in K or KL tumors was observed, as assessed by cleaved caspase-3 staining (Fig. 2B-D) . Next, to determine whether there is rapid tumor progression after initial sensitivity to Rankl inhibition, we treated the most aggressive model twice weekly with RANK-Fc or control Fc for a total duration of 3 weeks and monitored tumor growth rates longitudinally by mCT. Tumor growth remained compromised, indicating a durable response of primary lung adenocarcinoma to Rankl blockade (Fig. 2E) Similarly to the effect observed in K and KL mice, KP tumors were inherently sensitive to short-term Rankl blockade, although no change in tumor cell proliferation contrasting with that in KL tumors could be measured ( Fig. 3A and B) . Surprisingly, phospho-Erk was enhanced, suggesting a paradoxical Erk-dependent pathway activation in response to Rankl blocking therapy in KP tumors (Fig. 3C) . A 6-week treatment follow-up indicated a long-term response to Rankl blockade in KP mice (Fig. 3D) . Together, the results from Figures 2 and 3 demonstrate an inherent sensitivity and durable response to Rankl blockade in primary lung tumors in the mouse.
Rankl-Rank Expression Is Elevated in TumorAssociated Immune Cells, but Blockade Does Not Lead to Major Changes in the Tumor Immune Microenvironment
Next, we decided to better characterize the effect of Rankl blockade. Staining of tumor sections by immunohistochemistry showed Rank and Rankl expression in each of the K, KP, and KL tumors (Fig. 4A) . Monitoring by real-time polymerase chain reaction did not reveal any difference in Rankl expression between the tumor genotypes, although there was stronger Rank expression in KP than in K or KL tumors, thus contrasting with the human TCGA data (Fig. 4B) . Immunofluorescence staining enabled us to detect each of Rank and Rankl plasma membrane protein expression heterogeneously within the tumor mass, with Rank frequently colocalizing with E-cadherin and Rankl with CD45-positive (immune) cells (Fig. 4C-D) . To understand which cell types express Rankl and Rank, we collected lung tumors or healthy lung from KP mice and used anti-CD45 magnetic beads to separate nonimmune (CD45-negative) from immune (CD45-positive) cells. This revealed a stronger expression of Rankl in CD45-negative cells isolated from tumors (which consist mostly but not exclusively of tumor epithelial cells) than in CD45-negative cells from healthy lung, whereas Rank expression was not different (Fig. 4E) . In tumors, expression of Rankl and Rank was more elevated in immune than in nonimmune cells, with the strongest expression in B and T lymphocytes for Rankl and in myeloid cells for Rank (Fig. 4F-G) . Because of this strong expression in immune cells within lung tumors, we next wanted to know whether treatment causes remodeling of the tumor immune microenvironment. RANK-Fc led to a significant increase in Rankl expression in nonimmune cells and a reduction in immune cells, whereas there was no perturbation in Rank expression (Fig. 4H) . After 2 weeks of treatment, no change was observed in the proportion of B cells, whereas that of T lymphocytes diminished, which was not specific for any of the CD4-positive, T-regulatory, or CD8-positive subsets (Supplementary Fig. 2A-C) . Rankl blockade did not result in any significant change in the expression of tumor necrosis factor gene (Tnf), interleukin 10 gene (Il10), or interferon gamma gene (Ifng) mRNAs in CD45-positive or CD45-negative cells and did not alter cytoplasmic expression of interferon gamma or tumor necrosis factor proteins in CD4-positive or CD8-positive T cells (Supplementary Fig. 2D and E). RANK was originally characterized in dendritic cells and suggested to participate in dendritic cell-dependent T-cell expansion, a hypothesis that was not supported by analysis of Rank-deficient mice. 3, 4 Our results demonstrate that despite elevated Rank and Rankl expression in immune cells within the tumor microenvironment, Rankl blockade only marginally remodels the immune compartment, which does not support a major role for immune cells in the antitumor response.
Rankl Blockade Increases the Efficacy of Cisplatin Chemotherapy
To test the effect of combination treatment compared with monotherapy, we decided to treat tumor-bearing KP mice with RANK-Fc for 1 week followed by 1 week of standard chemotherapy cisplatin with maintenance of RANK-Fc and used mCT to compare tumor growth rates with those of tumors from mice treated with cisplatin alone. Short-term cisplatin caused a diminished tumor growth rate, as reported earlier, 25 which was not significantly different from RANK-Fc therapy (Fig. 5A) . Combined RANK-Fc and cisplatin led to a more profound effect on tumor growth (Fig. 5B) . When compared with cisplatin alone, combined therapy led to a significant decrease in the expression of the antiapoptotic genes Bcl-2-like protein 1 gene (Bcl2l1) and X-linked inhibitor of apoptosis gene (Xiap) in the tumor cell compartment, as well as to Xiap in immune cells and increased apoptosis revealed by cleaved caspase-3 ( Fig. 5C and D) . In contrast, there was no additive effect of the combination treatment compared with that of chemotherapy alone in KL tumors, maybe because RANK-Fc diminishes tumor cell proliferation and hence does not favor success of an antiproliferative drug (Supplementary Fig. 3) . Hence, our results highlight the efficacy of Rankl blockade in preclinical mouse models of lung adenocarcinoma. They suggest different mechanisms of action in different tumor molecular subtypes and that combination treatments will be more efficacious than chemotherapy alone in some but not all patients (Fig. 5E ).
Bcl2l1 and Xiap are known NF-kB target genes. Signaling by NF-kB directly in the tumor epithelial cells plays an important role in the development of lung tumors in mouse models of NSCLC, notably in tumors initiated upon oncogenic Kras activation. [26] [27] [28] [29] [30] [31] [32] However, how the NF-kB pathway becomes activated in NSCLC is currently unclear. Because NF-kB most often responds to cell stimulation by extracellular ligands such as cytokines of the interleukin-1 or TNF families, one plausible scenario is that the tumor microenvironment triggers NF-kB activation in tumor cells by paracrine communication. As it is a potent activator of NF-kB, RANKL could participate in the elaboration of an NF-kB response in lung tumor cells. 15 Indeed, RANKL stimulates migration of the A549 human lung tumor cell line through the upregulation of the NF-kB target gene intercellular adhesion molecule 1 gene (ICAM1). 33 In future preclinical and clinical investigations, it will therefore be important to test whether RANKL participates in lung tumor development partly through NF-kB activation, and whether NF-kB targets could be used as biomarkers of denosumab treatment efficacy in patients' tumors.
In our study, we have used mouse models where tumor initiation depends on oncogenic Kras activation, because (1) KRAS is the most commonly mutated protooncogene in human NSCLC, (2) these models faithfully recapitulate many aspects of the development of the human disease, and (3) these models are refractory to many treatments and are thus relevant to assess new therapeutic opportunities (here Rankl blockade). Our preclinical results, combined with our bioinformatics analyses, depict a strong connection between mutant KRAS and RANKL signaling in lung adenocarcinoma, which probably does not take place in CRC. Hence, our observations are generating the hypothesis that RANKL blockade will be efficient in KRAS-mutant lung tumors. An important future step will be to verify this hypothesis directly in tumor samples from patients.
Case Report of a Patient with Stage IV NSCLC Treated with Denosumab Monotherapy
A female patient, who was a former smoker with a 30-pack-year smoking history, presented with a middle lobe lung adenocarcinoma, EGFR WT, without anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement, cT4 cN0 cM1b (lower right lobe and bone metastases in the thoracolumbar spine especially L3, pelvis, femoral collar) stage IV. The adenocarcinoma was diagnosed on March 15, 2013 (by a transbronchial biopsy lower right lobe). The patient was hesitant regarding chemotherapy. Although she was presenting several painful bone metastases, an initial treatment of denosumab monotherapy was introduced as the first step in her oncology management, in parallel with supportive care including lumbar spine palliative radiotherapy in March. She decided to start chemotherapy on May 21, which was 2 months after the diagnosis. A new computed tomography scan was performed before she started undergoing chemotherapy, 4 weeks after a unique cycle of denosumab only, showing a primary lung tumor partial response ( Fig. 6A and B) . Thereafter, she received systemic chemotherapy (10 cycles [four platinum-pemetrexed and 6 pemetrexed], with partial response and thereafter with stable disease). She died 7 months after diagnosis.
This clinical case illustrates the potential efficacy, at least in select cases, of RANKL blockade therapy, even in advanced disease as monotherapy. Furthermore, the very large unplanned retrospective analysis of denosumab versus zoledronic acid in bone metastatic lung cancer 16 and our gene expression data set analyses of human lung adenocarcinoma both support the hypothesis of an improved OS. The activity of denosumab as an antineoplastic drug for the treatment of advanced NSCLC in combination with frontline platinum-based chemotherapy is currently being evaluated in the large randomized phase 3 European Organization for Research and Treatment of Cancer/European Thoracic Oncology Platform trial SPLENDOUR, with a primary end point of OS and a parallel retrospective analysis of RANK signaling pathway activation, including RANK and RANKL expression at baseline for all patients.
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